Topiramate Dosing for Binge Eating Disorder Starting at 25 mg Daily
Start with 25 mg daily and increase by 25-50 mg per week, titrating to a target dose of 200-400 mg/day (divided into two doses), with most patients responding at a median dose of 200-250 mg/day.
Recommended Titration Schedule
Based on the FDA labeling 1 and clinical trial evidence 2, 3, here is the practical dosing algorithm:
Week 1: 25 mg once daily (typically at bedtime to minimize side effects)
Week 2: 50 mg daily (can split to 25 mg twice daily or continue once daily)
Week 3: 75 mg daily (split dosing recommended: 25 mg morning, 50 mg evening)
Week 4: 100 mg daily (50 mg twice daily)
Week 5: 150 mg daily (75 mg twice daily)
Week 6: 200 mg daily (100 mg twice daily) - This is the minimum effective target dose
Weeks 7-8+: If needed, continue increasing by 50 mg/week up to maximum 400 mg/day (200 mg twice daily)
Key Dosing Considerations
Effective dose range: The 2023 WFSBP guidelines give topiramate a Level A evidence, Grade 1 recommendation for BED 4, with clinical trials showing efficacy at 200-400 mg/day 2, 3
Median effective dose: Most patients in controlled trials responded at approximately 200-250 mg/day 5, 2, so many patients won't need to go beyond 200 mg/day
Slower titration is better tolerated: The 25 mg/week increment minimizes discontinuation due to side effects, though the FDA label notes that 25-50 mg/week increments are acceptable 1
Monitoring and Response Assessment
- Assess response at 6-8 weeks after reaching 200 mg/day before increasing further
- Primary outcomes to track: binge episodes per week, binge days per week, and weight
- Clinical trials showed 94% reduction in binge frequency and 93% reduction in binge days at effective doses 2
Critical Safety Warnings
Common side effects leading to discontinuation include paresthesias (tingling), headache, cognitive slowing, and difficulty with concentration 1, 2. These are dose-related and often improve with slower titration.
Do not break tablets due to bitter taste 1
Adjust for renal impairment: Use half the usual dose if creatinine clearance <70 mL/min 1
High discontinuation rates: Studies show 14-20% discontinuation due to adverse events 5, 3, emphasizing the importance of slow titration and patient education about expected side effects
Clinical Context
While the 2023 APA guidelines suggest topiramate as a second-line option (preferring psychotherapy first) 6, the 2023 WFSBP guidelines give it equal standing with lisdexamfetamine as a first-line pharmacological option for BED 4. The choice between starting with 25 mg/week versus 50 mg/week titration should favor the slower approach given the 90% higher withdrawal rate for safety reasons compared to placebo 3.